Deals
Fresenius Buys Akorn for $4.3 Billion in U.S. Expansion
- German company will pay $34 a share for generics maker
- Fresenius also made smaller purchase of biosimilar business
This article is for subscribers only.
In just 10 months at the head of Germany’s Fresenius SE, Chief Executive Officer Stephan Sturm has now inked the health-care provider’s two biggest-ever deals.
With the $4.3 billion acquisition of Illinois-based generic drugmaker Akorn Inc., announced late Monday, Fresenius will get a stronger foothold in the U.S., with access to a network of retail pharmacies and outpatient clinics as well as the hospitals where it has traditionally marketed its products. Akorn will complement Fresenius’s Kabi medicines unit, which specializes in intravenous drugs.